CORRESPONDENCE

Re: The Association Between Statins and Cancer Incidence in a Veterans Population
I was pleased to read the article by Farwell et al. ( 1 ) reporting on statins and cancer. By comparing cancer incidence rates in statin users (irrespective of antihypertensive drug use) and antihypertensive drug users, the investigators likely limited detection bias that can arise in studies in which opportunity for exposure and outcome detection both depend on accessing medical care. For prostate cancer, detection bias has become of particular concern in epidemiological studies after the introduction of prostatespecific antigen (PSA) screening. Detection bias could arise when men who seek medical care are screened for both elevated cholesterol and PSA: compared with men who test negative, men who test positive for elevated cholesterol are more likely to be prescribed a statin, and men who test positive for elevated PSA are more likely to undergo biopsy examination. Consequently, men with prostate cancer who take a statin would be more likely diagnosed when their disease is organ confined, whereas men with prostate cancer who do not take a statin would be more likely diagnosed when their disease is advanced. Thus, statin use would appear associated positively with total and early disease and inversely with advanced disease.
Farwell et al. ( 1 ) reported a slight inverse association between statins and prostate cancer (relative risk = 0.90, 95% confi dence interval = 0.81 to 0.99) but no trend across dose. These fi ndings are somewhat different than for lung and colorectal cancers, which were moderately inversely associated ( 1 The possibility of detection bias was considered in the US prospective studies [see references in ( 2 )] by taking into account the notable difference between statin users and nonusers in the proportion of men who had a screening PSA test. This bias was likely reduced in the clinic-based casecontrol study ( 6 ) by including men who had a PSA test in the past year as control subjects. Further support that the inverse association is not solely due to detection bias comes from a study in Finland ( 7 ), where PSA screening is not common, and, thus, the correlation of cholesterol screening leading to statin use with PSA screening leading to biopsy may be lower. At this time, there is no compelling evidence to refute that statins may protect against advanced or high-grade prostate cancer, but detection bias cannot be ruled out as an explanation. Given a great strength of the study by Farwell et al. ( 1 ) -limited detection bias -I am eager to know the association between statin use and advanced prostate cancer in this study. ELIZABETH A . PLATZ
